CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in danish patients with rheumatoid arthritis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Krintel, Sophine B ^a   Essioux, Laurent ^b   Wool, Assaf ^c   Johansen, Julia S ^d,e   Schreiber, Ehud ^c   Zekharya, Tomer ^c   Akiva, Pinchas ^c   Østergaard, Mikkel ^a,e   Hetland, Merete L ^a,e  

^a Mental Health Services CPH   (Denmark)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Compugen Ltd ^*  (Israel)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BINDING PROTEIN; CD6 ANTIGEN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PROTEIN VARIANT; SYNTAXIN BINDING PROTEIN 6; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASE PAIRING; CD6 GENE; COMPUTER MODEL; CONTROLLED STUDY; DENMARK; DISEASE DURATION; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN GENOME; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNTAXIN BINDING PROTEIN 6 GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARRIER PROTEINS; COHORT STUDIES; DENMARK; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; INDEL MUTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84862011416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038539     Document Type: Article

References (46)

1. Lipsky PE, Van Der Heijde DM, St Clair EW, Furst DE, Breedveld FC, (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594-1602.
2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253-259.
3. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48: 35-45.
4. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62: 22-32.
5. Landewe RB, (2003) The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 48: 1-5.
6. Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Jarvenpaa S, (2010) Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 12: R122.
7. Hyrich KL, Watson KD, Silman AJ, Symmons DP, (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45: 1558-1565.
8. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, (2003) Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62: 526-529.
9. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, (2003) Polymorphism at position-308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48: 1849-1852.
10. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, (2004) The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50: 2750-2756.
11. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, (2006) Tumour necrosis factor (TNF)alpha-308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 35: 435-440.
12. Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, (2008) Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17: 3532-3538.
13. Toonen EJ, Coenen MJ, Kievit W, Fransen J, Eijsbouts AM, (2008) The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis 67: 1174-1177.
14. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, (2009) Influence of variants of Fc{gamma}receptors IIA and IIIA on the ACR and EULAR responses to anti-TNF{alpha} therapy in rheumatoid arthritis. Ann Rheum Dis 68: 1547-1552.
15. Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, (2010) Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 69: 1029-1035.
16. Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, (2009) Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics 19: 319-323.
17. Potter C, Gibbons LJ, Bowes JD, Cordell HJ, Hyrich K, (2010) Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenet Genomics 20: 338-341.
18. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, (2010) Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 69: 1315-1320.
19. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62: 1849-1861.
20. Soto L, Sabugo F, Catalan D, Wurmann P, Cermenatti T, (2011) The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) alpha-308 G/G promoter polymorphism. Clin Rheumatol 30: 391-395.
21. Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A, (2010) Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Ther 12: R72.
22. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, (2008) Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 14: 575-581.
23. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, (2011) Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 63: 645-653.
24. Mullaney JM, Mills RE, Pittard WS, Devine SE, (2010) Small insertions and deletions (INDELs) in human genomes. Hum Mol Genet 19: R131-R136.
25. Ku CS, Loy EY, Salim A, Pawitan Y, Chia KS, (2010) The discovery of human genetic variations and their use as disease markers: past, present and future. J Hum Genet 55: 403-415.
26. Hetland ML, (2011) DANBIO-powerful research database and electronic patient record. Rheumatology (Oxford) 50: 69-77.
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
29. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39: 34-40.
30. Dohn UM, Boonen A, Hetland ML, Hansen MS, Knudsen LS, (2009) Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 68: 1585-1590.
31. Sarrias MR, Gronlund J, Padilla O, Madsen J, Holmskov U, (2004) The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol 24: 1-37.
32. Nair P, Melarkode R, Rajkumar D, Montero E, (2010) CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol 162: 116-130.
33. Ibanez A, Sarrias MR, Farnos M, Gimferrer I, Serra-Pages C, (2006) Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 177: 1152-1159.
34. Coulthard LR, Taylor JC, Eyre S, Robinson JI, Wilson AG, (2011) Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 70: 98-103.
35. Hammaker D, Topolewski K, Edgar M, Yoshizawa T, Fukushima A, (2011) Decreased collagen-induced arthritis severity and adaptive immunity in mitogen activated protein kinase kinase 6-deficient mice. Arthritis Rheum; DOI 10.1002/art.33359.
36. Taylor J, Tyekucheva S, King DC, Hardison RC, Miller W, (2006) ESPERR: learning strong and weak signals in genomic sequence alignments to identify functional elements. Genome Res 16: 1596-604.
37. Lindberg J, af Klint E, Ulfgren AK, Stark A, Andersson T, (2006) Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther 8: R47.
38. Scales SJ, Hesser BA, Masuda ES, Scheller RH, (2002) Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. J Biol Chem 277: 28271-9.
39. Okada Y, Hirota T, Kamatani Y, Takahashi A, Ohmiya H, (2011) Identification of nine novel loci associated with white blood cell subtypes in a Japanese population. PLoS Genet 7: e1002067.
40. Prajapati R, Plant D, Barton A, (2011) Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 12: 1571-85.
41. Emery P, Dörner T, (2011) Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 70: 2063-70.
42. Plenge RM, Criswell LA, (2008) Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 20: 145-52.
43. NCI-NHGRI Working Group on Replication in Association Studies, Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, et al (2007) Replicating genotype-phenotype associations. Nature 447: 655-60.
44. Hansen NT, Brunak S, Altman RB, (2009) Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 86: 183-9.
45. Grant SF, Hakonarson H, (2007) Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Rev Mol Diagn 7: 371-93.
46. Cole SM, Long JC, (2008) A coalescent simulation of marker selection strategy for candidate gene association studies. Am J Med Genet B Neuropsychiatr Genet 147B: 86-93.